Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management.
Phellodendron amurense bark extract prevents progression of prostate tumors in transgenic adenocarcinoma of mouse prostate: potential for prostate cancer management.
复制标题
DOI：
--
复制
发表时间：
2010-03
影响因子：
2
通讯作者：
R. Ghosh;H. Graham;P. Rivas;Xi Tan;K. Crosby;S. Bhaskaran;J. Schoolfield;J. Banu;G. Fernandes;I. Yeh;Addanki P. Kumar
中科院分区：
文献类型：
--
作者：
R. Ghosh;H. Graham;P. Rivas;Xi Tan;K. Crosby;S. Bhaskaran;J. Schoolfield;J. Banu;G. Fernandes;I. Yeh;Addanki P. Kumar
前列腺癌是西方社会男性癌症相关死亡的第二大原因。流行病学研究表明，癌症风险降低与食用富含植物化学物质（包括水果和蔬菜）的饮食有关。延迟具有临床意义的前列腺癌的策略将对降低前列腺癌的总体发病率以及改善老年男性的生活质量产生巨大影响。此外，具有临床意义的前列腺癌的发展具有较长的潜伏期，为其治疗提供了大量的机会，特别是使用预防方法。我们实验室之前的研究表明，在转基因小鼠前列腺腺癌 (TRAMP) 模型中，在出现高级别前列腺上皮内瘤变之前给予 Nexrutine（黄柏树皮提取物）可预防前列腺肿瘤的发展。在这项研究中，我们通过给 28 周大的 TRAMP 小鼠施用 Nexrutine，研究了对 TRAMP 模型中已形成肿瘤进展的影响。 Nexrutine 的功效通过前列腺的组织病理学评估来确定。我们的数据表明，Nexrutine 抑制前列腺肿瘤的进展，这与转录因子核因子 kappa B、环 AMP 反应元件结合蛋白和磷酸化 CREB 的组织水平相关。此外，Nexrutine 干预导致左股骨骨干的骨矿物质密度显着增加 (p=0.009)，并防止转移性病变的发展。 Nexrutine 治疗还显着 (p=0.005) 抑制雄激素非依赖性前列腺癌细胞的侵袭。
Prostate cancer is the second leading cause of cancer-related deaths in men in Western society. Epidemiological studies suggest that a reduced risk of cancer is associated with the consumption of a phytochemical-rich diet that includes fruits and vegetables. Strategies to delay clinically significant prostate cancer will have a tremendous impact in reducing the overall incidence of prostate cancer as well as improving quality of life for elderly men. Furthermore, the long latency involved in the development of clinically significant prostate cancer provides a plethora of opportunities for its management, especially using prevention approaches. Previous studies from our laboratory show that Nexrutine (bark extract from Phellodendron amurense) prevents prostate tumor development when given prior to the development of high-grade prostatic intraepithelial neoplasia in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. In this study, we investigated the effect on the progression of established tumors in the TRAMP model by administering Nexrutine to 28-week-old TRAMP mice. Efficacy of Nexrutine was determined by histopathological evaluation of the prostate. Our data indicate that Nexrutine inhibited progression of prostate tumors that was correlated with tissue levels of transcription factors nuclear factor kappa B, cyclic-AMP response element-binding protein and phosphorylated CREB. Moreover, Nexrutine intervention resulted in a significant increase in the bone mineral density of the left femur diaphysis (p=0.009) and prevented the development of metastatic lesions. Nexrutine treatment also significantly (p=0.005) inhibited invasion of androgen-independent prostate cancer cells.